MX353649B - Proteinas protozoarias variables de superficie (vsp) como vehiculos para la administracion de farmacos. - Google Patents
Proteinas protozoarias variables de superficie (vsp) como vehiculos para la administracion de farmacos.Info
- Publication number
- MX353649B MX353649B MX2015000016A MX2015000016A MX353649B MX 353649 B MX353649 B MX 353649B MX 2015000016 A MX2015000016 A MX 2015000016A MX 2015000016 A MX2015000016 A MX 2015000016A MX 353649 B MX353649 B MX 353649B
- Authority
- MX
- Mexico
- Prior art keywords
- vsp
- carriers
- surface proteins
- protozoan
- variant
- Prior art date
Links
- 239000000969 carrier Substances 0.000 title abstract 3
- 102000018697 Membrane Proteins Human genes 0.000 title abstract 2
- 108010052285 Membrane Proteins Proteins 0.000 title abstract 2
- 238000012377 drug delivery Methods 0.000 title 1
- 229940126701 oral medication Drugs 0.000 title 1
- 239000003814 drug Substances 0.000 abstract 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 2
- 229940124597 therapeutic agent Drugs 0.000 abstract 2
- 241000224466 Giardia Species 0.000 abstract 1
- 102400000321 Glucagon Human genes 0.000 abstract 1
- 108060003199 Glucagon Proteins 0.000 abstract 1
- 102000004877 Insulin Human genes 0.000 abstract 1
- 108090001061 Insulin Proteins 0.000 abstract 1
- 230000002378 acidificating effect Effects 0.000 abstract 1
- 230000000975 bioactive effect Effects 0.000 abstract 1
- 230000015556 catabolic process Effects 0.000 abstract 1
- 238000006731 degradation reaction Methods 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- -1 e.g. Proteins 0.000 abstract 1
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 abstract 1
- 229960004666 glucagon Drugs 0.000 abstract 1
- 229940125396 insulin Drugs 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 230000017854 proteolysis Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2066—IL-10
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
Abstract
La presente invención se refiere a compuestos para la administración por vía oral y métodos de tratamiento que utilizan vehículo VSP, tales como las proteínas variables de superficie (VSP) de Giardia sp., para administrar agentes terapéuticos. Loa vehículos de fármacos VSP pueden ser combinados con péptidos bioactivos, por ej., insulina, glucagón o hGH, y se los puede administrar por vía oral o mucosal. Los vehículos VSP son resistentes a los pH acídicos y a la degradación proteolítica y protegen a los agentes terapéuticos de la degradación en el tracto intestinal.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261668865P | 2012-07-06 | 2012-07-06 | |
| US13/843,766 US9457096B2 (en) | 2012-07-06 | 2013-03-15 | Protozoan variant-specific surface proteins (VSP) as carriers for oral drug delivery |
| PCT/IB2013/001830 WO2014006502A1 (en) | 2012-07-06 | 2013-07-05 | Protozoan variant-specific surface proteins (vsp) as carriers for oral drug delivery |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2015000016A MX2015000016A (es) | 2015-10-29 |
| MX353649B true MX353649B (es) | 2018-01-22 |
Family
ID=49878968
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015000016A MX353649B (es) | 2012-07-06 | 2013-07-05 | Proteinas protozoarias variables de superficie (vsp) como vehiculos para la administracion de farmacos. |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US9457096B2 (es) |
| EP (2) | EP3398610B1 (es) |
| CN (1) | CN104994867A (es) |
| AR (1) | AR093225A1 (es) |
| AU (2) | AU2013285099A1 (es) |
| BR (1) | BR112015000183B1 (es) |
| CA (1) | CA2878322C (es) |
| MX (1) | MX353649B (es) |
| NZ (1) | NZ704285A (es) |
| WO (1) | WO2014006502A1 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115025239A (zh) | 2016-03-01 | 2022-09-09 | 阿森迪斯药物骨疾病股份有限公司 | Pth前药 |
| WO2018060310A1 (en) * | 2016-09-29 | 2018-04-05 | Ascendis Pharma Bone Diseases A/S | Dosage regimen for a controlled-release pth compound |
| ES2943720T3 (es) | 2016-09-29 | 2023-06-15 | Ascendis Pharma Bone Diseases As | Compuestos de PTH con bajas relaciones de pico a valle |
| CN107083961B (zh) * | 2017-05-10 | 2019-04-26 | 中国矿业大学 | 基于压裂圈的强地压巷道应力转移方法 |
| EP3466963A1 (en) * | 2017-10-05 | 2019-04-10 | Suigeneris Farmacosmetics, S.L. | Anticancer peptides and uses thereof |
| AU2020334967A1 (en) * | 2019-08-16 | 2022-04-07 | Applied Molecular Transport Inc. | Compositions and particles for payload delivery |
| EP4144752A1 (en) * | 2021-09-02 | 2023-03-08 | Sorbonne Universite | Viral-like particles for the treatment or prevention of an infection by a coronaviridae virus |
| KR20230083100A (ko) * | 2021-12-02 | 2023-06-09 | 삼성전자주식회사 | 폴리펩티드, 이를 포함하는 포토레지스트 조성물 및 이를 이용한 패턴 형성 방법 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4342832A (en) | 1979-07-05 | 1982-08-03 | Genentech, Inc. | Method of constructing a replicable cloning vehicle having quasi-synthetic genes |
| US5618697A (en) | 1982-12-10 | 1997-04-08 | Novo Nordisk A/S | Process for preparing a desired protein |
| US5547929A (en) | 1994-09-12 | 1996-08-20 | Eli Lilly And Company | Insulin analog formulations |
| EP1201750A1 (en) | 2000-10-26 | 2002-05-02 | Genopoietic | Synthetic viruses and uses thereof |
| NZ529572A (en) | 2001-05-21 | 2006-02-24 | Nektar Therapeutics | Pulmonary administration of chemically modified insulin |
| US6828297B2 (en) | 2001-06-04 | 2004-12-07 | Nobex Corporation | Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
| US7049286B2 (en) | 2001-08-30 | 2006-05-23 | Diatos, S.A. | Insulin conjugates and methods of use thereof |
| BR0312297A (pt) | 2002-07-18 | 2005-04-12 | Cytos Biotechnology Ag | Conjugados veìculos de hapteno e seu uso |
| EP1843790A2 (en) | 2005-01-27 | 2007-10-17 | Novo Nordisk A/S | Insulin derivatives conjugated with structurally well defined branched polymers |
| EP1893240A2 (en) | 2005-06-13 | 2008-03-05 | Nastech Pharmaceutical Company Inc. | Transmucosal delivery of peptide derivatives |
| ES2361166T3 (es) | 2005-07-08 | 2011-06-14 | Biocon Limited | Conjugados de insulina. |
| US8058391B2 (en) | 2005-10-13 | 2011-11-15 | Biocon Limited | Process for the preparation of insulin conjugate IN-105 |
| RU2451029C2 (ru) | 2006-05-09 | 2012-05-20 | Ново Нордиск А/С | Производное инсулина |
| PE20110942A1 (es) | 2008-12-02 | 2011-12-30 | Consejo Nac Invest Cient Tec | Protozoo modificado que expresa multiples proteinas variables de superficie (vsp), composicion inmunogenica que lo comprende y procedimientos |
| KR20110110253A (ko) | 2009-01-28 | 2011-10-06 | 스마트쎌스, 인크. | 결정질 인슐린-접합체 |
| US9801927B2 (en) | 2010-03-29 | 2017-10-31 | Centre National De La Recherche Scientifique-Cnrs | Pharmaceutical compositions comprising a polypeptide comprising at least one CXXC motif and heterologous antigens and uses thereof |
-
2013
- 2013-03-15 US US13/843,766 patent/US9457096B2/en active Active
- 2013-07-05 CN CN201380046431.5A patent/CN104994867A/zh active Pending
- 2013-07-05 MX MX2015000016A patent/MX353649B/es active IP Right Grant
- 2013-07-05 AU AU2013285099A patent/AU2013285099A1/en not_active Abandoned
- 2013-07-05 NZ NZ704285A patent/NZ704285A/en not_active IP Right Cessation
- 2013-07-05 CA CA2878322A patent/CA2878322C/en active Active
- 2013-07-05 WO PCT/IB2013/001830 patent/WO2014006502A1/en active Application Filing
- 2013-07-05 BR BR112015000183-1A patent/BR112015000183B1/pt active IP Right Grant
- 2013-07-05 EP EP18176440.8A patent/EP3398610B1/en active Active
- 2013-07-05 EP EP13760112.6A patent/EP2869829B1/en active Active
- 2013-07-05 US US14/413,189 patent/US9757471B2/en active Active
- 2013-07-08 AR ARP130102433A patent/AR093225A1/es not_active Application Discontinuation
-
2017
- 2017-08-09 US US15/673,037 patent/US20180228913A1/en not_active Abandoned
- 2017-11-24 AU AU2017265167A patent/AU2017265167B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| AU2013285099A1 (en) | 2015-02-19 |
| BR112015000183B1 (pt) | 2022-12-13 |
| EP3398610B1 (en) | 2020-09-09 |
| CA2878322A1 (en) | 2014-01-09 |
| US9457096B2 (en) | 2016-10-04 |
| CN104994867A (zh) | 2015-10-21 |
| EP3398610A1 (en) | 2018-11-07 |
| AU2017265167A1 (en) | 2017-12-14 |
| WO2014006502A1 (en) | 2014-01-09 |
| EP2869829B1 (en) | 2018-09-12 |
| CA2878322C (en) | 2021-11-16 |
| US20180228913A1 (en) | 2018-08-16 |
| US20140011739A1 (en) | 2014-01-09 |
| AR093225A1 (es) | 2015-05-27 |
| MX2015000016A (es) | 2015-10-29 |
| US9757471B2 (en) | 2017-09-12 |
| WO2014006502A8 (en) | 2014-12-11 |
| EP2869829A1 (en) | 2015-05-13 |
| BR112015000183A2 (pt) | 2018-03-20 |
| NZ704285A (en) | 2018-04-27 |
| US20150157735A1 (en) | 2015-06-11 |
| AU2017265167B2 (en) | 2019-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX353649B (es) | Proteinas protozoarias variables de superficie (vsp) como vehiculos para la administracion de farmacos. | |
| MX2019011215A (es) | Ácidos nucleicos que codifican proteínas asociadas a crispr y usos de los mismos. | |
| EA201491285A1 (ru) | Улучшенные композиции и способы доставки омепразола и ацетилсалициловой кислоты | |
| MX340822B (es) | Formulaciones para suministro oral de adsorbentes en el intestino. | |
| MX2012007806A (es) | Composiciones farmaceuticas para administracion oral de peptidos de insulina. | |
| MX2017004592A (es) | Formulaciones farmaceuticas para la administracion oral de farmacos peptidicos o proteinicos. | |
| MX2014001050A (es) | Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero. | |
| UA94734C2 (ru) | ТЕРАПЕВТИЧЕСКОЕ АНТИТЕЛО, КОТОРОЕ СВЯЗЫВАЕТСЯ С b-АМИЛОИДНЫМ ПЕПТИДОМ | |
| EA201290171A1 (ru) | Вводимые перорально кортикостероидные композиции | |
| WO2013084000A3 (en) | Exosomes for delivery of biotherapeutics | |
| EA201590622A1 (ru) | Конъюгаты для доставки лекарственного средства, содержащие не встречающиеся в природе аминокислоты, и способы применения | |
| MX355446B (es) | Tratamiento de rinitis. | |
| EA201490149A1 (ru) | Композиция и лекарственное средство, содержащие рекомбинантную человеческую идуронат-2-сульфатазу, и способ их получения | |
| WO2006138608A3 (en) | Pharmaceutical compositions and use thereof | |
| BR112012029975A2 (pt) | peptídeo como medicamento, em particular para o tratamento do câncer. | |
| WO2014145443A3 (en) | Liquids rich in noble gas and methods of their preparation and use | |
| MY157564A (en) | Combination pharmaceutical composition and methods of treating functional diseases or conditions of gastrointestinal tract | |
| MY167804A (en) | Treatment of degenerative joint disease | |
| WO2014044794A3 (en) | Pharmaceutical composition | |
| DE602008006700D1 (es) | ||
| IN2014DN03213A (es) | ||
| EP3164412A4 (en) | Pharmaceutical composition comprising recombinant hemoglobin protein or subunit-based therapeutic agent for cancer targeting treatment | |
| WO2012092305A3 (en) | Nanonized iron compositions and methods of use thereof | |
| IN2014CN00510A (es) | ||
| WO2014161004A3 (en) | Compositions and methods for the delivery of drugs to the ocular surface by contact lenses |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |